AudioCure Pharma GmbH

ACTIVE

Schlegelstr. 9, Berlin, Germanywww.audiocure.deHolding1–10 employeesEstablished: 2010-01-01

Clinical Trials

5 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2010

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

66.7%

Phase 2

22.2%

Trial Status Distribution

Active, not recruiting

55.6%

Completed

11.1%

Recruiting

33.3%

Clinical Trials

Trials sponsored by this organization (9)

A Study to Evaluate the Efficacy, Safety and Tolerability of a Single Injection of AC102 into the Middle Ear Compared to Oral Steroid Treatment in Patients with Sudden Hearing Loss.

Phase 1

Recruiting

interventional

Jun 2024207 participants

Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)

Phase 2

Active, not recruiting

interventional

Oct 2022210 participants

A Study to Evaluate the Efficacy, Safety and Tolerability of a Single Injection of AC102 into the Middle Ear Compared to Oral Steroid Treatment in Patients with Sudden Hearing Loss.

Phase 1

Active, not recruiting

Jan 2022210 participants

A Study to Evaluate the Efficacy, Safety and Tolerability of a Single Injection of AC102 into the Middle Ear Compared to Oral Steroid Treatment in Patients with Sudden Hearing Loss.

Phase 1

Recruiting

interventional

Jan 2022210 participants

A Study to Evaluate the Efficacy, Safety and Tolerability of a Single Injection of AC102 into the Middle Ear Compared to Oral Steroid Treatment in Patients with Sudden Hearing Loss.

Phase 1

Active, not recruiting

Jan 2022210 participants

A Study to Evaluate the Efficacy, Safety and Tolerability of a Single Injection of AC102 into the Middle Ear Compared to Oral Steroid Treatment in Patients with Sudden Hearing Loss.

Phase 1

Active, not recruiting

interventional

Dec 2021210 participants

A Study to Evaluate the Efficacy, Safety and Tolerability of a Single Injection of AC102 into the Middle Ear Compared to Oral Steroid Treatment in Patients with Sudden Hearing Loss.

Phase 1

Active, not recruiting

interventional

Dec 2021210 participants

First-in-human, placebo-controlled, ascending dose study to assess the safety, tolerability and pharmacokinetics of a single intratympanic injection of AC102 in healthy volunteers

Completed

interventional

42 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations